Clinical evaluation of promising conjugated serogroup C meningococcal vaccines is now well advanced, and development work at an earlier stage continues on candidate vaccines for serogroup B disease.Prospects for a reduction, and ultimately, elimination of meningococcal disease are good.
No takes yet. Share an insight, caveat, or question.
Cartwright et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: